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ABSTRACT 
Stabilizes inactivated state of sodium channels, thereby making neurons less excitable may reduce activity of nucleus ventralis of the thalamus or 
decrease synaptic transmission or summation of temporal stimulation leading to neuronal discharge.A adult of 68 years old patient came to 
dermatology department with chief complaints of neuralgia over scalp to relieve the symptoms physician prescribed carbamazepine 200mg Po 
OD. During his 2ndweek of treatment patient developed pain,fever,sore throat followed by skin rash.Better vigilance is necessary for 
implementation of safe and effective treatment for each individual patient.in order to  prevent serious adverse drug reactions of this drug,close 
monitoring drug treatment course, creating awareness, recognition of the problem and careful management of all the patients who receive 
medication are essential,because use of carbamazepine causes thrombocytopenia, leukopenia, leukocytosis, eosinophilia, anemia, pruritic 
and erythematous rashes, urticaria, photosensitivity reactions, alterations in skin pigmentation, exfoliative dermatitis, erythema multiforme and 
nodosum, purpura, aggravation of disseminated lupus erythematosus,Abnormalities in liver function tests, cholestatic and hepatocellular 
jaundice, hepatitis; very rare cases of hepatic failure, Pancreatitis ,Pulmonary hypersensitivity characterized by fever, dyspnea, pneumonitis, or 
pneumonia 
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Introduction 
Drug rash with eosinophilia and systemic symptoms 
(DRESS) syndrome is a rather distinct severe adverse drug 
reaction. However, use of the term DRESS has been 
inconsistent, because eosinophilia is not a constant clinical 
finding, cutaneous and systemic signs are variable. The 
estimated incidence of this syndrome ranges from 1 in 1000 
to 1 in 10,000 drug exposures, Adults are more affected than 
children 1. The main culprit drugs are carbamazepine and 
allopurinol, even though 50 drugs can induce DRESS 2. 
Another drug was reported particularly sulfa derivatives, 
antidepressants, non steroidal anti-inflammatory drugs, and 
antimicrobials. DRESS syndrome including a severe skin 
eruption, fever, hematologic abnormalities (eosinophilia or 
atypical lymphocytes), and internal organ involvement, 
usually 2-6 weeks after the initiation of drug therapy, with a 
possibility of persistence or aggravation of symptoms 
despite the discontinuation of the culprit drug. Given the 
potential morbidity, wide differential diagnosis, and 
relatively simple treatment, it is important for emergency 
physicians to consider this entity in patients with severe 
rashes. Severe cases of DRESS often require aggressive 
treatment; however, current pharmacologic treatment 
options are limited 
Case report 
A adult of 68 years old patient came to dermatology 
department with chief complaints of neuralgia over scalp to 
relieve the symptoms physician prescribed carbamazepine 
200mg Po OD. During his 2ndweek of treatment patient 
developed pain,fever,sore throat followed by skin rash.On 
general examination, patient was conscious and coherent.on 
physical examination PR-92/min,RR:16/min,spo2: 97% with 
RA,Resp: BAE+, CVS: S1 S2 +. Dermatological examination: 
skin- multiple, discrete  purpuric  popular, macular rash over 
trunk, thighs, upper limbs, lower left cervical 
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lymphadenopathy, left axillary lymphadenopathy, laboratory 
investigations CBP:Eosinophils-  101 (14%), LFT: aspartate 
aminotransferase (AST)- 84 U/L (10-35 U/L), alanine 
aminotransferase (ALT) 67 U/L (10-40 U/L), ultrasound 
abdomen shows splenomegaly,prostatomegaly,Lymph node 
enlargement>2,Patient was referred to physician of head of 
the department to confirm the ADR was due to phenytoin 
high dose .On analysis compared to all other drugs 
prescribed,phenytoin pharmacology and literature support 
the occurrence of irritability. In order to confirm the 
relationship between the effect and drug we have also done 
dechallenge test i.e.drug was withdrawn from treatment 
regimen 
Discussion 
The acronym “drug rash with eosinophilia and systemic 
symptoms” was first introduced in 1996 by Bocquet, to 
describe patients exhibiting a drug-induced condition 
characterized by an extensive rash, fever, lymphadenopathy, 
hematologic abnormalities, hepatitis, and involvement of the 
kidneys, lungs, heart, or pancreas 3. Usually presents within 
8week. Aromatic anticonvulsants (phenytoin, phenobarbital, 
and carbamazepine) are the most common cause of DRESS. 
In the review of 172 cases reported as DRESS or drug 
hypersensitivity syndrome in the literature by using the 
Regis CAR scoring system 4, carbamazepine remains the 
mostly reported (27% of cases). But a variety of other drugs, 
such as allopurinol, minocycline, dapsone, sulfasalazine, and 
mexiletine, antiretrovirals have also been associated with 
DRESS. Cross-sensitivity is as high as 75% among the 
aromatic anticonvulsants 5. 
The pathogenesis of DRESS syndrome is partially 
understood. Different mechanisms have been implicated in 
its development, including detoxification defects leading to 
reactive metabolite formation and subsequent 
immunological reactions slow acetylation, and reactivation 
of human herpes, including Epstein-Barr virus and human 
herpesvirus (HHV)-6 and -7. The detection of HHV-6 
reactivation has even been recently proposed as a diagnostic 
marker for DRESS. Other types of viral infection were 
reported, such as cytomegalovirus reactivation and 
paramyxovirus infection. It is increasingly apparent that 
there is a genetic predisposition to adverse drug reactions. 
Studies have found that HLA-B*1502 is associated with 
carbamazepine induced Stevens-Johnson syndrome /toxic 
epidermal necrolysis in some Asian populations, but the 
same association does not occur in hypersensitivity 
syndrome (HSS) / DRESS. It is hoped that further research 
may define pharmacogenetic disease susceptibility markers 
to identify people at high risk of developing HSS / DRESS, 
Regis CAR and Japanese consensus group have developed 
specific criteria for making the diagnosis of DRESS. To meet 
the definition of DRESS, patients must have three of the four 
main Regis CAR criteria: an acute rash, fever above 38° C, 
lymphadenopathy at two sites, involvement of at least one 
internal organ, and abnormalities in lymphocyte and 
eosinophil counts. Additional criteria include hospitalization 
and that the reaction is suspected to be drug-related. 
Concerning Japanese consensus group the diagnosis requires 
meeting seven of the nine criteria in this system or all of the 
first five: a maculopapular rash developing > 3 weeks after 
drug initiation, clinical symptoms continuing > 2 weeks after 
stopping therapy, fever > 38° C, liver abnormalities (ALT > 
100 IU/L) or other organ involvement, leukocytosis, atypical 
lymphocytes, eosinophilia, lymphadenopathy, or HHV-6 
reactivation. Although an association with HHV6 is of 
interest, definite confirmation that herpes viruses are central 
to the hypersensitivity reaction is currently lacking. An 
ambiguous role for virus reactivation coupled with low 
availability of the relevant assay reduces the worth of HHV6 
as diagnostic criteria. 
The patient described here met the majority of criteria 
according to Regis CAR scoring guidelines for a diagnosis of 
DRESS induced by carbamazepine. 
Conclusion 
Although the mechanisms underlying DRESS syndrome 
remain poorly understood. This is a growing case reported in 
literature. The diagnosis of dress should be highly suspected 
with the presence of skin rash, liver involvement, fever, 
hypereosinophilia, and lymphadenopathy particularly in 
starting any new anti-epileptic. The use of systemic 
corticosteroids is classically reported in case of organ- or 
life-threatening disease. However, this remains controversial 
and may lead to activation of HHV- 6. Besides the prompt 
withdrawal of causative drug as standard of care, further 
studies are needed to recommend specific treatment 
guidelines. 
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